Ticino Pharmaceutical Success | Frontaliere Ticino
Ticino Pharmaceutical Success — free tools and expert guides for cross-border workers (frontalieri) between Switzerland and Italy. Compare salaries, tax, LAMal health insurance, pensions, and cost of living in Ticino. Updated 2026.
Context
2025 was a record year for the two leading Swiss pharmaceutical companies, Roche and Novartis, which continue to dominate the global market with exceptional financial results. Roche reported a 7% increase in sales, reaching 61.5 billion francs, driven by strong demand for multiple sclerosis drugs, eye diseases, and hemophilia A treatments. CEO Thomas Schinecker described 2025 as 'a record year' for the company, emphasizing the importance of investments in research and development, which exceeded 12 billion francs in 2025. Novartis also experienced a significant increase in sales of its flagship products, such as the Kymriah drug for leukemia treatment, with a 30% rise in CEO Vas Narasimhan's compensation, now earning around 10 million francs. In 2025, Novartis recorded sales of 58 billion francs, thanks to an innovation strategy that brought several gene therapies to market. Both companies, based in Basel and operating in Ticino, are among the top tax contributors in Switzerland, paying approximately 4 billion francs in taxes annually. They employ about 25,000 people across the country, with around 4,500 in the Ticino canton, in municipalities like Lugano and Mendrisio. 📊 For companies operating in the pharmaceutical sector, it is crucial to adhere to various regulations, such as the Public Health Act of 2021, which introduced provisions for safeguarding public health and promoting innovation. ⚠️ Companies also face challenges related to bureaucracy and compliance requirements, such as registering new drugs with Swissmedic, which can take up to 12 months for approval. 💡 An operational checklist for pharmaceutical companies in Ticino includes: - Monitoring local and national regulations - Investing in R&D to maintain competitiveness - Collaborating with universities...
Operational details
Despite the positive results, politicians and industry representatives are calling for urgent reforms to keep Switzerland attractive for the pharmaceutical industry. Over the past decade, the biopharmaceutical sector has contributed 40% to the country's economic growth, generating about 7% of GDP, equivalent to around 50 billion Swiss francs in 2022. Switzerland hosts the headquarters of Roche and Novartis in Basel, which together invested over 10 billion francs in research and development in 2021. The Canton of Ticino, due to its strategic location, stands out for logistics and research, hosting important distribution and innovation centers. In particular, municipalities like Lugano and Mendrisio have seen a significant increase in biotech start-ups, with over 30 new companies founded since 2020. The University of Italian Switzerland (USI) and the University of Applied Sciences and Arts of Southern Switzerland (SUPSI) are prominent academic institutions collaborating with pharmaceutical companies for research and development of new drugs. In 2023, USI received 5 million francs in funding for a gene therapy research project in partnership with Novartis. The Federal Department of Finance (FDF) and the State Secretariat for Economic Affairs (SECO) are involved in defining economic and tax policies concerning the sector. Recent tax reform proposals included in the 'Tax Proposal 2024' package aim to further incentivize investments in the pharmaceutical sector by lowering the corporate tax rate from 21% to 18% for companies investing in R&D. 📊 Operational checklist for pharmaceutical companies: - Tax regulation analysis: Monitor tax changes and incentive opportunities. - Collaboration with academic institutions: Establish partnerships with universities for research proje...
Key points
For cross-border workers in the pharmaceutical sector in Ticino, it is essential to understand the specific regulations and job opportunities, especially considering the current economic context. Use our salary calculator to assess your skills and potential salary. For example, a professional with experience as a clinical researcher in Lugano can earn between CHF 80,000 and CHF 120,000 per year, depending on experience and qualifications. Additionally, it is crucial to stay updated on tax policies and reforms that may impact your work and tax contributions. Since January 1, 2023, Ticino has introduced new tax rates that may affect cross-border workers' income, so consulting a tax expert is advisable to understand the impact on your finances. The original source of this news is available on RSI. Publication date: yesterday. ## Practical tips - Check your skills and potential salary using online tools, such as salary reports from specific pharmaceutical companies based in municipalities like Mendrisio and Bellinzona. - Stay updated on tax policies and reforms affecting the pharmaceutical sector; for instance, the new 2023 tax decree includes an increase in income tax for cross-border workers, raising the rate to 12% for incomes over CHF 100,000. - Consider enhancing your professional skills through training courses, such as those offered by local universities or vocational training programs in collaboration with industry companies. ### Operational checklist - Review your current tax situation and compare rates with other countries. - Update your resume and LinkedIn profile with the latest skills acquired. - Attend job fairs and networking events in the pharmaceutical sector to increase your employment opportunities. 📊 For example, if you work in the biotechnology sec...